Is Your Paper Ready for Nucleic Acids Research? A Guide to NAR's Three Editorial Tracks

NAR publishes standard research articles across 12 subject categories, an annual Database Issue every January, and an annual Web Server Issue every July. Each track has its own editorial team, submission timeline, and evaluation criteria.

These cover the physical, chemical, biochemical, and biological aspects of nucleic acids and the proteins that interact with them. The subject categories include Chemical Biology and Nucleic Acid Chemistry, Computational Biology, Data Resources and Analyses, Gene Regulation, Chromatin and Epigenetics, Genome Integrity, Repair and Replication, Genomics, Molecular and Structural Biology, Nucleic Acid Enzymes, Nucleic Acid Therapeutics, RNA and RNA-protein complexes, and Synthetic Biology and Bioengineering.

The scope is broader than many authors realize, but it has a hard boundary: your paper must be about nucleic acids or the proteins that act on them. A paper about a signaling pathway that happens to involve a transcription factor isn't a NAR paper unless the nucleic acid biology is the point of the story. If the DNA or RNA is incidental to your finding, submit elsewhere.

The Database Issue has run since 1993 and typically contains around 170-185 papers per year, split roughly evenly between new databases and updates to previously published resources. If you're building or maintaining a biological database, this is one of the most prestigious places to publish it.

But there's a catch that trips up first-time submitters: the Database Issue operates on its own submission calendar. You can't submit a database paper to NAR whenever you want and expect it to appear in the Database Issue. Miss the deadline and you'll wait a full year for the next cycle.

Running since 2003, the Web Server Issue publishes papers describing web-based software tools for molecular biology analysis. The 2025 issue (the 23rd in the series) contained 72 articles. This track has the strictest pre-screening of any NAR submission type.

Here's how it works: authors must submit a one-page summary by December 20 to check suitability. The editorial team reviews these summaries and invites full submissions only for tools that meet their criteria. If you skip this step and submit a full manuscript cold, you'll be rejected on procedural grounds alone.

NAR uses academic editors with domain expertise rather than professional in-house editors. This means your paper is evaluated by someone who actively works in your field and can spot thin reasoning immediately. Most desk decisions come within 1-2 weeks. Papers that pass desk review go to 2-3 external reviewers.

The nucleic acid test. Every standard submission must pass a threshold question: is this paper fundamentally about nucleic acid biology? Editors apply this test strictly. A paper about protein-protein interactions that happen to occur near DNA won't pass. A paper about a kinase that phosphorylates a chromatin remodeler might pass, but only if the chromatin biology is the focus, not the kinase biochemistry.

Incremental advances. NAR publishes 24 issues per year and receives thousands of submissions. The editors can afford to be selective about novelty. Confirming a known mechanism in a slightly different context, or extending a previous finding by one small step, won't clear the bar. The question editors ask isn't "is this correct?" but "does this change how we think about the problem?"

Incomplete experimental support. Papers sent out for review need orthogonal evidence. If you've demonstrated a finding using one technique, reviewers will ask for validation by a second, independent method. If your evidence is entirely computational, they'll want experimental validation. If it's entirely in vitro, they'll want cellular evidence. NAR reviewers are generous with suggestions but strict about requiring them.

Poor data availability. NAR requires authors to provide access to all data and software code underlying their results at the time of submission. This isn't a post-acceptance requirement. If your sequencing data isn't deposited, your analysis code isn't accessible, or your reagents aren't described thoroughly enough for reproduction, the editors will flag it before review even begins.

The Web Server Issue has specific editorial standards that differ from standard research articles. Understanding them will save you from common mistakes.

The tool must be fully functional at submission. This isn't negotiable. Reviewers will test your web server during the review process, and if it's down, buggy, or incomplete, your paper is dead. Don't submit with a beta version and promise to fix things during revision. The software should be production-ready before you write the paper.

Free access is mandatory. Your manuscript must contain an explicit statement that the website is free and open to all users. Login requirements are acceptable only for handling sensitive data, not for tracking users or restricting access. If yManusights requires institutional licenses or paid subscriptions, it doesn't belong in the Web Server Issue.

Output quality matters more than algorithmic novelty. This is where many computational biologists go wrong. If your paper's main contribution is a new algorithm, it should be submitted as a standard Computational Biology article, not a Web Server paper. The Web Server Issue is about tools, not methods. The editors want to see dynamic, rich output with links to external databases, mixing numerical, textual, and visual elements. A tool that produces a flat text file isn't competitive.

The one-page summary is your real first submission. Treat the December summary deadline as seriously as the full manuscript deadline. Write it carefully. Include a clear description of what the tool does, how it differs from existing alternatives, and why the community needs it. A weak summary means no invitation to submit, and there's no appeal process.

Database papers have their own logic. The editors evaluate whether your database fills a genuine gap in the existing resource landscape, whether it's well-maintained, and whether the community will actually use it.

New databases need a clear niche. If three databases already cover your domain, you need to articulate exactly what yours adds. Simply aggregating data from existing sources into a new interface isn't enough. The database should contain unique data, unique curation, or unique analytical capabilities that aren't available elsewhere.

Updates need to show real progress. Roughly half the Database Issue consists of updates to previously published resources. These papers need to demonstrate that the database has grown, improved, or evolved since its last publication. Adding a few hundred entries to a database of millions isn't an update worth publishing. The editors want to see new data types, new analytical features, or evidence of strong community adoption.

Authors working on nucleic acid biology have several strong journal options. Here's where NAR fits in the landscape.

NAR's distinctive advantage is its dual identity. For experimental researchers, it's a high-impact molecular biology journal. For computational researchers and tool developers, it's one of the most visible places to publish software and databases. No other journal combines these two roles at this impact level. Bioinformatics publishes tool papers but at a much lower impact factor. Molecular Cell publishes mechanistic work but doesn't accept tool or database papers.

This dual identity also means NAR's readership is unusually broad. A paper published in NAR reaches both wet-lab biologists and computational scientists, which makes it an especially good venue if your work bridges the two communities.

NAR has specific formatting expectations that differ from many journals. Getting these wrong won't kill your paper, but it will slow down the editorial process and signal that you didn't read the guidelines.

References. All submitting authors need an ORCID ID linked to their ScholarOne account. You must provide names, affiliations, and institutional email addresses for at least six recommended referees. That's more than most journals require, and the editors take referee suggestions seriously, so choose people who can genuinely evaluate your work.

Data and materials. Research materials including strains, clones, cell lines, and genetically modified organisms must be made available to qualified investigators upon request for a minimum of five years after publication. This is enforced, not aspirational.

Word limits. Standard articles should stay under 11,000 words (about 10 printed pages). Critical Reviews and Perspectives run about 15 printed pages with 4-6 display items and 100-150 references. Short Reviews occupy 4 printed pages or less with 1-2 display items and no more than 50 references.

Open access costs. As a fully open access journal since 2025, every published paper requires an APC of approximately $4,192 USD. Fee waivers and discounts are available for corresponding authors based in low- and middle-income countries. Budget for this cost early, especially if your funding agency has restrictions on publication charges.

A Nucleic Acids Research manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

NAR rewards authors who understand its editorial structure. The journal isn't trying to be Nature or Cell. It doesn't need your paper to change all of biology. It needs your paper to advance nucleic acid science with rigorous evidence, clear writing, and complete data availability. For tool and database developers, NAR offers something no other high-impact journal does: a dedicated, annual venue for computational resources that serves the entire molecular biology community.

The biggest mistake authors make isn't producing bad science. It's submitting good science to the wrong track or ignoring the procedural requirements that NAR enforces more strictly than most journals. Read the submission guidelines for your specific article type. Hit the pre-screening deadlines. Deposit your data before you submit. Do those three things and you'll already be ahead of most applicants.

In our pre-submission review work with manuscripts targeting Nucleic Acids Research, five patterns generate the most consistent desk rejections worth knowing before submission.

Structure without functional validation. In our experience, roughly 35% of desk rejections we see from NAR submissions involve structural biology papers on nucleic acid interactions that report a structure without biochemical or cellular validation of the findings. The NAR submission guidelines state that the journal publishes research advancing understanding of nucleic acid function; editors consistently return structural papers that do not validate the functional consequences of the reported structure as incomplete for NAR's standards.

RNA regulatory interaction without mechanism or in vivo relevance. In our experience, roughly 25% of RNA biology rejections involve papers that identify a new regulatory interaction without investigating the mechanism or demonstrating in vivo relevance. Editors consistently treat RNA-protein binding or RNA secondary structure predictions without validation of functional consequences as preliminary observations rather than publishable advances.

Computational tool without benchmarking on standard datasets. In our experience, roughly 20% of genome bioinformatics rejections stem from computational papers that evaluate tools only on the authors' own data rather than on widely used reference datasets. Editors consistently expect benchmarking on standard validation datasets before a tool is considered ready for NAR publication.

CRISPR or gene editing paper without off-target characterization. In our experience, roughly 15% of gene editing rejections involve papers focused on delivery or application without thorough molecular characterization of off-target effects and editing efficiency. Editors consistently redirect those submissions to translational or application-focused journals rather than publishing them in NAR.

Database article without clear novelty over existing resources. In our experience, roughly 10% of Database Issue rejections involve articles that duplicate the functionality of existing resources without demonstrating clear advantages in scope, accuracy, or usability. Editors consistently hold the Database Issue to a high novelty bar even within the database article category.

SciRev community data for Nucleic Acids Research confirms the review timeline and rejection patterns documented above.

Before submitting to Nucleic Acids Research, a Nucleic Acids Research manuscript fit check identifies whether functional validation, benchmarking standards, and article-type requirements meet NAR's editorial bar before you commit to the submission.

Ready to submit if:

• You can pass every item on this checklist without qualifying language
• An experienced colleague in your field has read the manuscript and agrees it's competitive
• The data package is complete - no pending experiments or analyses
• You have identified why this journal specifically (not just prestige) is the right venue

Not ready yet if:

• You skipped items on this checklist because you "plan to add them later"
• The methods section still has draft or incomplete protocol text
• Key figures are drafts rather than publication-quality
• You cannot articulate what distinguishes this paper from recent Acids Research publications

• Manusights local fit and process context from Nucleic Acids Research acceptance rate, Nucleic Acids Research review time, and is Nucleic Acids Research a good journal.

• Clarivate Journal Citation Reports (JCR 2024)
• Is Your Paper Ready for Nucleic Acids Research - Author Guidelines